Greylin Investment Mangement Decreased Its Teva Pharmaceutical Inds LTD (TEVA) Position; Acxiom (ACXM)’s Sentiment Is 1.55

January 13, 2018 - By Winifred Garcia

Greylin Investment Mangement Inc decreased Teva Pharmaceutical Inds Ltd (TEVA) stake by 21.95% reported in 2017Q3 SEC filing. Greylin Investment Mangement Inc sold 64,630 shares as Teva Pharmaceutical Inds Ltd (TEVA)’s stock declined 15.11%. The Greylin Investment Mangement Inc holds 229,865 shares with $4.05M value, down from 294,495 last quarter. Teva Pharmaceutical Inds Ltd now has $22.42 billion valuation. The stock increased 1.52% or $0.33 during the last trading session, reaching $22.07. About 40.56 million shares traded or 52.06% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since January 13, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.

Acxiom Corporation operates as a technology and enablement services firm in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $2.23 billion. The firm operates through three divisions: Connectivity, Audience Solutions, and Marketing Services. It currently has negative earnings. The Connectivity segment provides a foundational identity resolution layer, which enables its clients to identify and reach clients across channels and measure the impact of marketing on sales.

Analysts await Acxiom Corporation (NASDAQ:ACXM) to report earnings on January, 30. They expect $0.11 earnings per share, down 31.25% or $0.05 from last year’s $0.16 per share. ACXM’s profit will be $8.72M for 63.93 P/E if the $0.11 EPS becomes a reality. After $0.02 actual earnings per share reported by Acxiom Corporation for the previous quarter, Wall Street now forecasts 450.00% EPS growth.

Ratings analysis reveals 67% of Acxiom’s analysts are positive. Out of 3 Wall Street analysts rating Acxiom, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $30.0 while the high is $36.0. The stock’s average target of $32.33 is 14.93% above today’s ($28.13) share price. ACXM was included in 3 notes of analysts from September 15, 2016. First Analysis downgraded it to “Equal-Weight” rating and $30.0 target in Friday, November 18 report. The stock of Acxiom Corporation (NASDAQ:ACXM) earned “Buy” rating by Cantor Fitzgerald on Thursday, September 15. Dougherty & Company maintained it with “Buy” rating and $36.0 target in Friday, November 18 report.

Rgm Capital Llc holds 11.58% of its portfolio in Acxiom Corporation for 4.55 million shares. Ibis Capital Partners Llp owns 274,617 shares or 6.5% of their US portfolio. Moreover, Falcon Point Capital Llc has 1.86% invested in the company for 510,156 shares. The New York-based Diker Management Llc has invested 1.31% in the stock. Granite Investment Partners Llc, a California-based fund reported 728,750 shares.

The stock increased 0.14% or $0.04 during the last trading session, reaching $28.13. About 222,611 shares traded. Acxiom Corporation (ACXM) has risen 34.36% since January 13, 2017 and is uptrending. It has outperformed by 17.66% the S&P500.

Among 33 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 7 Sell and 17 Hold. Therefore 27% are positive. Teva Pharma had 127 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Wednesday, October 4 with “Hold”. Piper Jaffray maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Friday, October 6. Piper Jaffray has “Hold” rating and $23.0 target. As per Monday, July 18, the company rating was upgraded by HSBC. Leerink Swann initiated Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Tuesday, January 2. Leerink Swann has “Sell” rating and $15.0 target. Citigroup maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Tuesday, July 28. Citigroup has “Buy” rating and $86 target. The firm earned “Hold” rating on Thursday, June 22 by Jefferies. The firm has “Hold” rating given on Thursday, August 3 by Cantor Fitzgerald. Cowen & Co maintained the stock with “Outperform” rating in Wednesday, April 5 report. J.P. Morgan downgraded Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Monday, November 13. J.P. Morgan has “Sell” rating and $11.0 target. The firm has “Neutral” rating given on Friday, June 16 by Cantor Fitzgerald.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>